Track Vivoryon Therapeutics N.V. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Vivoryon Therapeutics N.V. 05Y.F · Stock Open Vivoryon Therapeutics N.V. in new tab

1.24 EUR
Add to portfolio
EPS
-0.33
P/B
7.72
ROE
-140.45
Beta
1.38
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-0.33
Book Value0.16
Price to Book7.72
Debt/Equity2.29
% Insiders21.455%

DCF Valuation

Tweak assumptions to recompute fair value for Vivoryon Therapeutics N.V. (05Y.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Vivoryon Therapeutics N.V. Logo Vivoryon Therapeutics N.V. Analysis (05Y.F)

Germany Health Care Official Website Stock

Is Vivoryon Therapeutics N.V. a good investment? Vivoryon Therapeutics N.V. (05Y.F) is currently trading at 1.24 EUR.

Investor FAQ

Does Vivoryon Therapeutics N.V. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Vivoryon Therapeutics N.V.?

Vivoryon Therapeutics N.V. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.

Exchange Ticker
FRA (Germany) 05Y.F
AMS (Netherlands) VVY.AS
GER (Germany) 05Y.DE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion